Alkermes plc - Ordinary Shares (ALKS): Price and Financial Metrics
GET POWR RATINGS... FREE!
ALKS POWR Grades
- Growth is the dimension where ALKS ranks best; there it ranks ahead of 99.76% of US stocks.
- The strongest trend for ALKS is in Quality, which has been heading down over the past 179 days.
- ALKS ranks lowest in Momentum; there it ranks in the 12th percentile.
ALKS Stock Summary
- ALKS's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 138.33 -- higher than 82.94% of US-listed equities with positive expected earnings growth.
- Alkermes plc's stock had its IPO on July 16, 1991, making it an older stock than 83.46% of US equities in our set.
- Price to trailing twelve month operating cash flow for ALKS is currently 44.57, higher than 88.09% of US stocks with positive operating cash flow.
- Stocks that are quantitatively similar to ALKS, based on their financial statements, market capitalization, and price volatility, are THRM, MRIN, CLXT, ACLS, and SMSI.
- ALKS's SEC filings can be seen here. And to visit Alkermes plc's official web site, go to www.alkermes.com.
ALKS Valuation Summary
- In comparison to the median Healthcare stock, ALKS's EV/EBIT ratio is 519.45% lower, now standing at -122.9.
- Over the past 243 months, ALKS's EV/EBIT ratio has gone down 53.7.
- ALKS's price/sales ratio has moved down 32.4 over the prior 243 months.
Below are key valuation metrics over time for ALKS.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ALKS | 2021-08-31 | 4.6 | 4.6 | -80.3 | -122.9 |
| ALKS | 2021-08-30 | 4.6 | 4.6 | -80.7 | -123.4 |
| ALKS | 2021-08-27 | 4.6 | 4.6 | -79.9 | -122.3 |
| ALKS | 2021-08-26 | 4.5 | 4.5 | -78.4 | -120.1 |
| ALKS | 2021-08-25 | 4.5 | 4.5 | -78.7 | -120.6 |
| ALKS | 2021-08-24 | 4.5 | 4.5 | -78.0 | -119.5 |
ALKS Growth Metrics
- Its 3 year revenue growth rate is now at 75.07%.
- The 4 year price growth rate now stands at -65.14%.
- The 5 year cash and equivalents growth rate now stands at -11.96%.
The table below shows ALKS's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-12-31 | 1,173.751 | 101.715 | -48.169 |
| 2021-09-30 | 1,129.283 | 138.037 | -91.684 |
| 2021-06-30 | 1,100.154 | 115.463 | -62.83 |
| 2021-03-31 | 1,043.966 | 77.968 | -94.625 |
| 2020-12-31 | 1,038.756 | 82.842 | -110.861 |
| 2020-09-30 | 1,171.491 | 57.569 | -73.573 |
ALKS's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ALKS has a Quality Grade of B, ranking ahead of 88.71% of graded US stocks.
- ALKS's asset turnover comes in at 0.582 -- ranking 63rd of 680 Pharmaceutical Products stocks.
- OTLK, AVEO, and LXRX are the stocks whose asset turnover ratios are most correlated with ALKS.
The table below shows ALKS's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.582 | 0.835 | -0.047 |
| 2021-06-30 | 0.576 | 0.836 | -0.029 |
| 2021-03-31 | 0.556 | 0.835 | -0.050 |
| 2020-12-31 | 0.557 | 0.828 | -0.061 |
| 2020-09-30 | 0.641 | 0.845 | -0.034 |
| 2020-06-30 | 0.646 | 0.844 | -0.076 |
ALKS Price Target
For more insight on analysts targets of ALKS, see our ALKS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $26.50 | Average Broker Recommendation | 1.88 (Hold) |
ALKS Stock Price Chart Interactive Chart >
ALKS Price/Volume Stats
| Current price | $30.29 | 52-week high | $33.00 |
| Prev. close | $30.39 | 52-week low | $21.24 |
| Day low | $29.91 | Volume | 1,104,400 |
| Day high | $30.57 | Avg. volume | 1,469,318 |
| 50-day MA | $28.65 | Dividend yield | N/A |
| 200-day MA | $26.86 | Market Cap | 4.95B |
Alkermes plc - Ordinary Shares (ALKS) Company Bio
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. The company was founded in 1987 and is based in Dublin, Ireland.
Latest ALKS News From Around the Web
Below are the latest news stories about Alkermes plc that investors may wish to consider to help them evaluate ALKS as an investment opportunity.
For Individuals With Bipolar 1 Disorder Finding the Right Treatment Can Be a Long and Difficult ProcessOur recent survey conducted with Harris Poll and Depression and Bipolar Support Alliance found that many individuals with Bipolar 1 disorder felt that finding the right treatment can be a long and ... |
Black History Month and Mental Health#BlackHistoryMonth represents an opportunity to highlight the disparities within the Black community when it comes to mental health. According to a 2018 survey, 50% of Black adults with serious men... |
Alkermes (ALKS) Gets a Buy Rating from Mizuho SecuritiesIn a report released today, Vamil Divan from Mizuho Securities reiterated a Buy rating on Alkermes (ALKS – Research Report), with a price target of $35.00. The company's shares closed last Wednesday at $26.79. According to TipRanks.com, Divan is a 1-star analyst with an average return of -2.1% and a 48.1% success rate. Divan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, ACADIA Pharmaceuticals, and Xeris Pharmaceuticals. Currently, the analyst consensus on Alkermes is a Moderate Buy with an average price target of $29.33, which is a 23.5% upside from current levels. |
Alkermes Reports Stellar Quarterly Beat; Shares Surge 15%Alkermes (NASDAQ: ALKS) shares jumped almost 15% on February 16, after the company delivered impressive fourth-quarter results topping both earnings and revenue estimates. Furthermore, the company provided strong FY2022 guidance and provided bullish long-term profitability targets. Alkermes is a global biopharmaceutical company that develops innovative medicines in the fields of neuroscience and oncology. Q4 Beat Markedly, adjusted earnings of $0.23 per share more than doubled year-over-year and significantly beat analysts’ expectations of $0.11 per share. The company reported earnings of $0.10 per share for the prior-year period. Further, revenues jumped 15.9% year-over-year to $324.5 million and exceeded consensus estimates of $308.88 million. |
Alkermes'' Nemvaleukin Shows Encouraging Anti-Tumor Activity In Pretreated Kidney CancerAlkermes plc (NASDAQ: ALKS ) presented new data from the ongoing phase 1/2 ARTISTRY-1 trial for nemvaleukin alfa, engineered interleukin-2 (IL-2) variant immunotherapy for advanced renal cell carcinoma (RCC). The data were presented at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium. The presentation includes updated efficacy and safety data from the monotherapy arm of ARTISTRY-1, in which … Full story available on Benzinga.com |
ALKS Price Returns
| 1-mo | 1.47% |
| 3-mo | 7.95% |
| 6-mo | 30.22% |
| 1-year | 23.53% |
| 3-year | 32.56% |
| 5-year | -47.75% |
| YTD | 30.22% |
| 2021 | 16.59% |
| 2020 | -2.21% |
| 2019 | -30.87% |
| 2018 | -46.08% |
| 2017 | -1.53% |
Continue Researching ALKS
Want to see what other sources are saying about Alkermes plc's financials and stock price? Try the links below:Alkermes plc (ALKS) Stock Price | Nasdaq
Alkermes plc (ALKS) Stock Quote, History and News - Yahoo Finance
Alkermes plc (ALKS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...